Cargando…

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer

Radioactive-labelled ligands targeting the prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed in prostate cancer (PC), have shown promising activity in treatment of metastatic castration-resistant prostate cancer (mCRPC). PSMA-617 and PSMA-I&T (imaging and therapy),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lunger, Lukas, Tauber, Robert, Feuerecker, Benedikt, Gschwend, Jürgen E., Eiber, Matthias, Heck, Matthias M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Management of Advanced Genitourinary Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575563/ https://www.ncbi.nlm.nih.gov/pubmed/34804839 http://dx.doi.org/10.21037/tau-20-1135

Ejemplares similares

Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review
por: Maurice Dror, Corinne, et al.
Publicado: (2021)

A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer
por: Fonseca, Nicolette M., et al.
Publicado: (2021)

KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021)

ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis
por: Schlack, Katrin, et al.
Publicado: (2021)

Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review
por: Ong, Sean, et al.
Publicado: (2021)

Narrative review of challenges in the management of advanced neuroendocrine prostate cancer
por: Okasho, Kosuke, et al.
Publicado: (2021)

Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging—utilization of a short-pass filter to reduce technical pitfalls
por: Darr, Christopher, et al.
Publicado: (2021)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
por: Babst, Christa, et al.
Publicado: (2022)

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

(177)Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art
por: AlSadi, Rahaf, et al.
Publicado: (2022)

Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Narrative review of developing new biomarkers for decision making in advanced testis cancer
por: Nappi, Lucia, et al.
Publicado: (2021)

Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review
por: Schulz, Gerald B., et al.
Publicado: (2021)

Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature
por: Gust, Kilian M., et al.
Publicado: (2021)

Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review
por: Giudici, Nicola, et al.
Publicado: (2021)

Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2021)

Systemic treatment of penile squamous cell carcinoma—hurdles and hopes of preclinical models and clinical regimens: a narrative review
por: Thomas, Anita, et al.
Publicado: (2021)

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study
por: Stein, Mark N, et al.
Publicado: (2022)

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer
por: Kostos, Louise, et al.
Publicado: (2023)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

Preface to “Management of advanced genitourinary malignancies”
por: Todenhöfer, Tilman
Publicado: (2021)

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
por: Mehra, Niven, et al.
Publicado: (2022)

Extragastrointestinal stromal tumor presenting as an exophytic prostatic mass
por: Nguyen Thanh, Thao, et al.
Publicado: (2020)

Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters
por: Shariftabrizi, Ahmad, et al.
Publicado: (2023)

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
por: Heck, Matthias M., et al.
Publicado: (2013)

Case series: Diffusion weighted MRI appearance in prostatic abscess
por: Singh, Paramjeet, et al.
Publicado: (2011)

Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
por: Boegemann, Martin, et al.
Publicado: (2021)

Adoption of Lutetium-(177) PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020
por: Flegar, Luka, et al.
Publicado: (2023)

Multimodality approach to imaging giant multilocular cystadenoma of the prostate: A rare entity
por: El-Asmar, Jose M., et al.
Publicado: (2019)

Giant multilocular prostatic cystadenoma, a diagnosis to consider in large pelvic male masses
por: Portugal Teixeira, Inês, et al.
Publicado: (2019)

A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer
por: Joshi, Amit, et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges
por: Oh, So Won, et al.
Publicado: (2018)

Diffusion-Weighted Magnetic Resonance Imaging for the Evaluation of Prostate Cancer: Optimal B Value at 3T
por: Koo, Ji Hyun, et al.
Publicado: (2013)

Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer
por: Fütterer, Jurgen J.
Publicado: (2017)

Transformation of adenocarcinoma of prostate to squamous cell carcinoma following hormonal treatment: A case report and review of the literature
por: Lee, Jihyun
Publicado: (2019)

Biexponential Apparent Diffusion Coefficients Values in the Prostate: Comparison among Normal Tissue, Prostate Cancer, Benign Prostatic Hyperplasia and Prostatitis
por: Liu, Xiaohang, et al.
Publicado: (2013)

Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review
por: Koshkin, Vadim S., et al.
Publicado: (2021)

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Freeman, Meredith N, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_crkddncsorksfu0aqsj9oj2blr